Ischemic CardiomyopathyREVIVED-BCIS2NCT01920048
Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure
A study testing Percutaneous Coronary Intervention, Drug Therapy for Heart Failure and Device Therapy for Heart Failure in people with Ischemic Cardiomyopathy, run by King's College London at 40 sites in United Kingdom.
Trial summary
This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Cardiomyopathy
- What is being tested?
- Percutaneous Coronary Intervention, Drug Therapy for Heart Failure and Device Therapy for Heart Failure
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 700 participants
- Where
- 40 sitesUnited Kingdom
- Study dates
- 28 Aug 2013to 31 Mar 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ALL of the following:
- Poor left ventricular function (EF≤35%)
- Extensive coronary disease
- Viability in at least 4 dysfunctional segments that can be revascularised by PCI
Who cannot join
- Myocardial infarction < 4 weeks prior to randomisation (clinical definition)
- Decompensated heart failure requiring inotropic support, invasive or non-invasive ventilation or Intra-aortic Balloon Pump/left ventricular assist device therapy <72 hours prior to randomization
- Sustained Ventricular Tachycardia/Ventricular Fibrillation or appropriate Implantable Cardioverter Defibrillator discharges <72 hours prior to randomization
- Valve disease requiring intervention
- Contraindications to percutaneous coronary intervention
- Age <18 yrs
Show all 10Show fewer
- Estimated Glomerular Filtration Rate < 25 ml/min, unless established on dialysis
- Women who are pregnant
- Previously enrolled in REVIVED-BCIS2 or current enrollment in other study that may affect REVIVED-BCIS2 outcome data
- Life expectancy < 1 yr due to non-cardiac pathology
Trial locations and contacts
40 sites in 1 country.
40 sites in 1 country
United Kingdom40 sites
Basingstoke and North Hampshire Hospital
Basingstoke, RG24 9NA
Royal Victoria Hospital
Belfast, BT12 6BA
Birmingham Heartlands Hospital
Birmingham, B9 5SS
Blackpool Victoria Hospital
Blackpool, FY3 8NR
North Wales Cardiac Centre
Bodelwyddan, LL18 5UJ
Royal Bournemouth Hospital
Bournemouth, BH7 7DW
Bristol Heart Institute
Bristol, BS2 8HW
University Hospital Coventry
Coventry, CV2 2DX
Dorset County Hospital
Dorchester, DT1 2JY
Ninewells Hospital
Dundee, DD1 9SY
Royal Infirmary of Edinburgh
Edinburgh, EH16 4SA
Royal Devon and Exeter Hospital
Exeter, EX2 5DW
Golden Jubilee National Hospital
Glasgow, G81 4DY
Kettering General Hospital
Kettering, NN16 8UZ
Leeds General Infirmary
Leeds, LS1 3EX
Glenfield Hospital
Leicester, LE3 9QP
Liverpool Heart and Chest Hospital
Liverpool, L14 3PE
Barts Heart Centre
London, EC1A 7BE
Royal Free Hospital
London, NW3 2QG
Guy's and St Thomas' Hospital
London, SE1 7EH
King's College Hospital
London, SE5 9RS
St George's Hospital
London, SW17 0QT
Manchester Royal Infirmary
Manchester, M13 9WL
The James Cook University Hospital
Middlesbrough, TS4 3BW
Freeman Hospital
Newcastle, NE7 7DN
Royal Oldham Hospital
Oldham, OL1 2JH
Derriford Hospital
Plymouth, PL6 8DH
Queen Alexandra Hospital
Portsmouth, PO6 3LY
Salisbury District Hospital
Salisbury, SP2 8BJ
Northern General Hospital
Sheffield, S5 7AU
Southampton General Hospital
Southampton, SO16 6YD
Lister Hospital
Stevenage, SG1 4AB
Sunderland Royal Hospital
Sunderland, SR4 7TP
Great Western Hospital
Swindon, SN3 6BB
Pinderfields Hospital
Wakefield, WF1 4DG
New Cross Hospital
Wolverhampton, WV10 0QP
Worcestershire Royal Hospital
Worcester, WR5 1DD
Worthing Hospital
Worthing, BN11 2DH
Wythenshawe Hospital
Wythenshawe, M23 9LT
York Hospital
York, YO31 8HE
About this study
Official title: REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease
This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy.
- Conditions
- Ischemic Cardiomyopathy
- Being tested
- Percutaneous Coronary Intervention, Drug Therapy for Heart Failure, Device Therapy for Heart Failure
- Keywords
- Heart Failure, Ventricular Dysfunction, Ischemic Cardiomyopathy, Ischemic Heart Disease, Revascularization, Percutaneous Coronary Intervention, Randomized Control Trial, Implantable Cardioverter Defibrillator
- Medical subject headings
- Heart Failure, Ventricular Dysfunction, Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Percutaneous Coronary InterventionProcedure or surgery
Also called Coronary angioplasty/stents
Drug Therapy for Heart FailureDrug
The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
Device Therapy for Heart FailureDevice
The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
| Study group | Role | What they receive |
|---|---|---|
| Percutaneous Coronary Intervention and Optimal Medical Therapy | Experimental | Not described Receives: Procedure: Percutaneous Coronary Intervention; Drug: Drug Therapy for Heart Failure; Device: Device Therapy for Heart Failure |
| Optimal Medical Therapy alone | Active comparator | Not described Receives: Drug: Drug Therapy for Heart Failure; Device: Device Therapy for Heart Failure |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause death or Hospitalization for Heart Failure
This composite endpoint will be collected over the entire duration of follow-up in the trial when the last patient randomized has reached 2 years of follow-up post randomization
Measured: 1 to 103 months (min follow-up duration: 24 months)
Secondary outcomes (12)
Left Ventricular Ejection Fraction
Left Ventricular Ejection Fraction (LVEF) on echocardiography
Measured: 6 months, 1 year
Quality of Life Scores
Kansas City Cardiomyopathy questionnaire (KCCQ) up to 2 years EuroQol EQ-5D-5L at 6 months and then yearly to the end of follow-up.
Measured: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years
New York Heart Association Functional (NYHA) Class
Measured: 6 months, 1 year, 2 years
Cardiovascular Death
Cardiovascular death over the entire duration of follow-up
Measured: 1 to 103 months (min follow-up duration: 24 months)
All-cause death
All-cause death over the entire duration of follow-up
Measured: 1 to 103 months (min follow-up duration: 24 months)
Hospitalization due to heart failure
Hospitalization due to heart failure over the entire duration of follow-up
Measured: 1 to 103 months (min follow-up duration: 24 months)
Acute Myocardial Infarction
Acute myocardial infarction (MI) over the entire duration of follow-up
Measured: 1 to 103 months (min follow-up duration: 24 months)
Appropriate Implantable Cardioverter Defibrillator Therapy
Appropriate implantable cardioverter defibrillator (ICD) therapy to 2 years
Measured: 6 months, 1 year, 2 years
Unplanned further revascularization
Unplanned further revascularization over the entire duration of follow-up
Measured: 1 to 103 months (min follow-up duration: 24 months)
Canadian Cardiovascular Society class
Canadian Cardiovascular Society (CCS) class up to 2 years
Measured: 6 months, 1 year, 2 years
Brain-type Natriuretic Peptide level
Brain natriuretic peptide (BNP or NT-Pro BNP) up to 2 years
Measured: 6 months, 1 year, 2 years
Major Bleeding
Major bleeding up to 2 years
Measured: 6 months, 1 year, 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2013 (estimated)
- Study start28 Aug 2013
- Primary completion19 Mar 2020
- Study completion31 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Ischemic CardiomyopathyStudies of the same condition, open and under way.
- More trials run by King's College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 700 participants (actual)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, London School of Hygiene and Tropical Medicine, University of York, Guy's and St Thomas' NHS Foundation Trust
- Responsible party
- Principal investigator, Divaka Perera, King's College London
- Investigators
- Divaka Perera, MB BChir, MA, MD, FRCP, Principal investigator, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01920048
- Sponsor's protocol ID
- ISRCTN45979711
- Other IDs
- ISRCTN45979711
- Acronym
- REVIVED-BCIS2
- Status last verified
- May 2022
- First submitted
- 3 Aug 2013
- Last updated
- 31 May 2022
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Ovesen C, Dodd M, Ryan M, Clayton T, Sharples L, Perera D. Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction-a prespecified analysis of REVIVED-BCIS2. Eur Heart J Qual Care Clin Outcomes. 2025 Dec 19;11(8):1440-1447. doi: 10.1093/ehjqcco/qcaf108.
PubMed 40972554Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, Morgan HP, Pavlidis A, Weerackody R, Walsh SJ, Spratt JC, Strange J, Ludman P, Chiribiri A, Clayton T, Petrie MC, O'Kane P, Perera D; REVIVED-BCIS2 Investigators. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. 2024 Jul 23;84(4):340-350. doi: 10.1016/j.jacc.2024.04.043. Epub 2024 May 15.
PubMed 38759904Ryan M, Taylor D, Dodd M, Spertus JA, Kosiborod MN, Shaukat A, Docherty KF, Clayton T, Perera D, Petrie MC; REVIVED-BCIS2 Investigators. Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction: Insights From REVIVED-BCIS2. JACC Heart Fail. 2024 Sep;12(9):1553-1562. doi: 10.1016/j.jchf.2024.03.010. Epub 2024 Apr 8.
PubMed 38727649Chivardi C, Morgan H, Sculpher MJ, Clayton T, Evans R, Dodd M, Petrie M, Rinaldi CA, O'Kane P, Brown L, Perera D, Saramago P; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial. Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010533. doi: 10.1161/CIRCOUTCOMES.123.010533. Epub 2023 Nov 6.
PubMed 37929587Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, Weerackody R, O'Kane PD, Masci PG, Nazir MS, Papachristidis A, Chahal N, Khattar R, Ezad SM, Kapetanakis S, Dixon LJ, De Silva K, McDiarmid AK, Marber MS, McDonagh T, McCann GP, Clayton TC, Senior R, Chiribiri A; REVIVED-BCIS2 Investigators. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. 2023 Dec 1;8(12):1154-1161. doi: 10.1001/jamacardio.2023.3803.
PubMed 37878295Perera D, Morgan HP, Ryan M, Dodd M, Clayton T, O'Kane PD, Greenwood JP, Walsh SJ, Weerackody R, McDiarmid A, Amin-Youssef G, Strange J, Modi B, Lockie T, Hogrefe K, Ahmed FZ, Behan M, Jenkins N, Abdelaal E, Anderson M, Watkins S, Evans R, Rinaldi CA, Petrie MC; REVIVED-BCIS2 Investigators. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial. Circulation. 2023 Sep 12;148(11):862-871. doi: 10.1161/CIRCULATIONAHA.123.065300. Epub 2023 Aug 9.
PubMed 37555345Ezad SM, Ryan M, Perera D. Can Percutaneous Coronary Intervention Revive a Failing Heart? Heart Int. 2022 Dec 21;16(2):72-74. doi: 10.17925/HI.2022.16.2.72. eCollection 2022.
PubMed 36741102Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, Morgan HP, Dodd M, Evans R, Canter R, Arnold S, Dixon LJ, Edwards RJ, De Silva K, Spratt JC, Conway D, Cotton J, McEntegart M, Chiribiri A, Saramago P, Gershlick A, Shah AM, Clark AL, Petrie MC; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27.
PubMed 36027563Perera D, Clayton T, Petrie MC, Greenwood JP, O'Kane PD, Evans R, Sculpher M, Mcdonagh T, Gershlick A, de Belder M, Redwood S, Carr-White G, Marber M; REVIVED investigators. Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. JACC Heart Fail. 2018 Jun;6(6):517-526. doi: 10.1016/j.jchf.2018.01.024.
PubMed 29852933
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease
- ClinicalTrials.gov ID
- NCT01920048
- Acronym / sponsor ID
- REVIVED-BCIS2 / ISRCTN45979711
- Conditions
- Ischemic Cardiomyopathy
- Keywords
- Heart Failure, Ventricular Dysfunction, Ischemic Cardiomyopathy, Ischemic Heart Disease, Revascularization, Percutaneous Coronary Intervention, Randomized Control Trial, Implantable Cardioverter Defibrillator
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 700 participants (actual)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, London School of Hygiene and Tropical Medicine, University of York, Guy's and St Thomas' NHS Foundation Trust
- Study start
- 28 Aug 2013 (actual)
- Primary completion
- 19 Mar 2020 (actual)
- Study completion
- 31 Mar 2022 (actual)
- First posted
- 9 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Percutaneous Coronary Intervention and Optimal Medical Therapy | Experimental | Procedure: Percutaneous Coronary Intervention, Drug: Drug Therapy for Heart Failure, Device: Device Therapy for Heart Failure |
| Optimal Medical Therapy alone | Active comparator | Drug: Drug Therapy for Heart Failure, Device: Device Therapy for Heart Failure |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Poor left ventricular function (EF≤35%)
- Extensive coronary disease
- Viability in at least 4 dysfunctional segments that can be revascularised by PCI
Key exclusion criteria (10 listed)
- Myocardial infarction < 4 weeks prior to randomisation (clinical definition)
- Decompensated heart failure requiring inotropic support, invasive or non-invasive ventilation or Intra-aortic Balloon Pump/left ventricular assist device therapy <72 hours prior to randomization
- Sustained Ventricular Tachycardia/Ventricular Fibrillation or appropriate Implantable Cardioverter Defibrillator discharges <72 hours prior to randomization
- Valve disease requiring intervention
- Contraindications to percutaneous coronary intervention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Percutaneous Coronary InterventionAlso: Coronary angioplasty/stents | Procedure or surgery | Percutaneous Coronary Intervention and Optimal Medical Therapy |
| Drug Therapy for Heart FailureThe optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines | Drug | Optimal Medical Therapy alone, Percutaneous Coronary Intervention and Optimal Medical Therapy |
| Device Therapy for Heart FailureThe optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy. | Device | Optimal Medical Therapy alone, Percutaneous Coronary Intervention and Optimal Medical Therapy |
Primary outcome
All-cause death or Hospitalization for Heart Failure
Time frame: 1 to 103 months (min follow-up duration: 24 months)
This composite endpoint will be collected over the entire duration of follow-up in the trial when the last patient randomized has reached 2 years of follow-up post randomization
12 secondary outcomes
Left Ventricular Ejection Fraction
Time frame: 6 months, 1 year
Quality of Life Scores
Time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years
New York Heart Association Functional (NYHA) Class
Time frame: 6 months, 1 year, 2 years
Cardiovascular Death
Time frame: 1 to 103 months (min follow-up duration: 24 months)
All-cause death
Time frame: 1 to 103 months (min follow-up duration: 24 months)
Hospitalization due to heart failure
Time frame: 1 to 103 months (min follow-up duration: 24 months)
Acute Myocardial Infarction
Time frame: 1 to 103 months (min follow-up duration: 24 months)
Appropriate Implantable Cardioverter Defibrillator Therapy
Time frame: 6 months, 1 year, 2 years
Unplanned further revascularization
Time frame: 1 to 103 months (min follow-up duration: 24 months)
Canadian Cardiovascular Society class
Time frame: 6 months, 1 year, 2 years
Brain-type Natriuretic Peptide level
Time frame: 6 months, 1 year, 2 years
Major Bleeding
Time frame: 6 months, 1 year, 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2022.
- Derived from this study: PubMed 40972554Ovesen C, Dodd M, Ryan M, Clayton T, Sharples L, Perera D. Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction-a prespecified analysis of REVIVED-BCIS2. Eur Heart J Qual Care Clin Outcomes. 2025 Dec 19;11(8):1440-1447. doi: 10.1093/ehjqcco/qcaf108.
- Derived from this study: PubMed 38759904Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, Morgan HP, Pavlidis A, Weerackody R, Walsh SJ, Spratt JC, Strange J, Ludman P, Chiribiri A, Clayton T, Petrie MC, O'Kane P, Perera D; REVIVED-BCIS2 Investigators. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. 2024 Jul 23;84(4):340-350. doi: 10.1016/j.jacc.2024.04.043. Epub 2024 May 15.
- Derived from this study: PubMed 38727649Ryan M, Taylor D, Dodd M, Spertus JA, Kosiborod MN, Shaukat A, Docherty KF, Clayton T, Perera D, Petrie MC; REVIVED-BCIS2 Investigators. Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction: Insights From REVIVED-BCIS2. JACC Heart Fail. 2024 Sep;12(9):1553-1562. doi: 10.1016/j.jchf.2024.03.010. Epub 2024 Apr 8.
- Derived from this study: PubMed 37929587Chivardi C, Morgan H, Sculpher MJ, Clayton T, Evans R, Dodd M, Petrie M, Rinaldi CA, O'Kane P, Brown L, Perera D, Saramago P; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial. Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010533. doi: 10.1161/CIRCOUTCOMES.123.010533. Epub 2023 Nov 6.
- Derived from this study: PubMed 37878295Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, Weerackody R, O'Kane PD, Masci PG, Nazir MS, Papachristidis A, Chahal N, Khattar R, Ezad SM, Kapetanakis S, Dixon LJ, De Silva K, McDiarmid AK, Marber MS, McDonagh T, McCann GP, Clayton TC, Senior R, Chiribiri A; REVIVED-BCIS2 Investigators. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. 2023 Dec 1;8(12):1154-1161. doi: 10.1001/jamacardio.2023.3803.
- Derived from this study: PubMed 37555345Perera D, Morgan HP, Ryan M, Dodd M, Clayton T, O'Kane PD, Greenwood JP, Walsh SJ, Weerackody R, McDiarmid A, Amin-Youssef G, Strange J, Modi B, Lockie T, Hogrefe K, Ahmed FZ, Behan M, Jenkins N, Abdelaal E, Anderson M, Watkins S, Evans R, Rinaldi CA, Petrie MC; REVIVED-BCIS2 Investigators. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial. Circulation. 2023 Sep 12;148(11):862-871. doi: 10.1161/CIRCULATIONAHA.123.065300. Epub 2023 Aug 9.
- Derived from this study: PubMed 36741102Ezad SM, Ryan M, Perera D. Can Percutaneous Coronary Intervention Revive a Failing Heart? Heart Int. 2022 Dec 21;16(2):72-74. doi: 10.17925/HI.2022.16.2.72. eCollection 2022.
- Derived from this study: PubMed 36027563Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, Morgan HP, Dodd M, Evans R, Canter R, Arnold S, Dixon LJ, Edwards RJ, De Silva K, Spratt JC, Conway D, Cotton J, McEntegart M, Chiribiri A, Saramago P, Gershlick A, Shah AM, Clark AL, Petrie MC; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27.
- Derived from this study: PubMed 29852933Perera D, Clayton T, Petrie MC, Greenwood JP, O'Kane PD, Evans R, Sculpher M, Mcdonagh T, Gershlick A, de Belder M, Redwood S, Carr-White G, Marber M; REVIVED investigators. Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. JACC Heart Fail. 2018 Jun;6(6):517-526. doi: 10.1016/j.jchf.2018.01.024.
Related trials for Ischemic Cardiomyopathy
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Recruiting
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
RecruitingObservational study
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Coronary Artery Disease, Myocarditis
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Divaka Perera, MB BChir, MA, MD, FRCP principal investigator
King's College London
40 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Percutaneous Coronary Intervention, Drug Therapy for Heart Failure and Device Therapy for Heart Failure in people with Ischemic Cardiomyopathy, run by King's College London at 40 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 40 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All-cause death or Hospitalization for Heart Failure (time frame: 1 to 103 months (min follow-up duration: 24 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01920048, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2022.